The market has been high on Windtree Therapeutics Inc (WINT) stock recently. WINT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.
Windtree Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on WINT!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With WINT Stock Today?
Windtree Therapeutics Inc (WINT) stock is lower by -8.62% while the S&P 500 is higher by 0.45% as of 1:43 PM on Friday, Dec 1. WINT has fallen -$0.10 from the previous closing price of $1.16 on volume of 128,210 shares. Over the past year the S&P 500 has risen 12.46% while WINT has fallen -88.99%. WINT lost -$20.24 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Windtree Therapeutics Inc click here.
More About Windtree Therapeutics Inc
Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.
Click Here to get the full Stock Report for Windtree Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
